---
schema_version: "secwatch.filing_event.v1"
accession: "0001567264-24-000003"
form_type: "8-K"
ticker: "INTS"
cik: "0001567264"
company_name: "INTENSITY THERAPEUTICS, INC."
filed_at: "2024-04-19T23:59:59+00:00"
generated_at: "2026-06-03T15:58:44.991421+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Intensity Therapeutics receives Nasdaq non-compliance notice after director resigns from audit committee

## Summary
- Daniel Donovan resigned from audit committee on April 12, 2024, leaving only 2 members; company received Nasdaq deficiency letter on April 18, 2024.
- Cure period runs until earlier of next annual stockholder meeting or April 14, 2025; if annual meeting before Oct 9, 2024, then cure expires Oct 9, 2024.
- Company intends to appoint a new independent director to the board to serve on the audit committee within the cure period.
- Failure to regain compliance could result in delisting; company may appeal any delisting determination to a hearings panel.

## SEC filing metadata
- accession: 0001567264-24-000003
- form_type: 8-K
- ticker: INTS
- cik: 0001567264
- company_name: INTENSITY THERAPEUTICS, INC.
- filed_at: 2024-04-19T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1567264/000156726424000003/0001567264-24-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1567264/000156726424000003/intensity-20240418.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001567264-24-000003
- JSON: https://secwatch.observer/filing/0001567264-24-000003.json
- Plain text: https://secwatch.observer/filing/0001567264-24-000003.txt

## Key facts
- Listing & Compliance Notices
  INTENSITY THERAPEUTICS, INC. received a nasdaq deficiency notice notice regarding audit committee (rules 5605(c)(2)(A), 5605(c)(4), 5605(a)(2), 10A-3).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: audit committee
  - Rules: 5605(c)(2)(A), 5605(c)(4), 5605(a)(2), 10A-3
  source text: April 18, 2024, the Company received a letter (the "Letter") from Nasdaq notifying the Company that, as a result of the resignation of Daniel Donovan from the Audit Committee, the Company is not in compliance with Nasdaq’s audit committee composition requirements as set forth in Nasdaq Listing Rule 5605. The Letter further provides that, pursuant to Nasdaq Listing Rule 5605(c)(4), the Company is entitled to a cure period to regain compliance with Nasdaq Listing Rule 5605, which cure period will expire the earlier of the Company's next annual stockholders' meeting or April 14, 2025; or if the n
  evidence_url: https://www.sec.gov/Archives/edgar/data/1567264/000156726424000003/0001567264-24-000003-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.